Printer Friendly

BIACORE'S NEW ADVANCED SYSTEM SET TO DRAMATICALLY REDUCE DRUG DISCOVERY AND DEVELOPMENT BOTTLENECKS; BIACORE LAUNCHES NEW HIGH PERFORMANCE ANALYTICAL SYSTEM.

Biacore International AB (Biacore) (Nasdaq:BCOR)(SSE:BCOR) has launched its Biacore S51 system for lead characterization and preclinical applications in drug discovery. This is the first system to be developed from Biacore's new Series S technology platform and is designed to address major analytical problems facing the pharmaceutical industry. Specifically, the system is expected to reduce critical bottlenecks in drug discovery at stages downstream of high-throughput screening (HTS), by providing more biological information on compound activity in a single assay than any technology available today.

As the pharmaceutical industry comes under increasing pressure to develop drugs faster and more efficiently, one of the crucial rate-limiting steps is the conversion of HTS 'hits' into lead compounds for preclinical evaluation. Biacore S51 is specifically designed to rapidly and efficiently address key steps in the 'hit'-to-lead selection process, by combining the advantage of Biacore's non-label Surface Plasmon Resonance (SPR) technology with advanced instrumentation and software for higher throughput, enhanced data quality and reduced sample usage.

The high quality, quantitative data produced offers unparalleled insight into the binding kinetics, affinity, concentration and specificity of the interaction between a compound and target molecule.

Biacore's SPR technology is unique in providing real-time kinetic data from assay formats that require no tags or labeling of compounds, enabling interactions to be studied in near-native states. This offers an unrivalled view of true functionality. Developed in collaboration with companies including Millennium Pharmaceuticals Inc, SmithKline Beecham and Pharmacia Corp, Biacore S51 represents the most advanced commercially available SPR-based instrument.

Launched in conjunction with Biacore S51 is a new customer support and assay development program called TecEdge. This unique package provides unparalleled access to Biacore's worldwide team of application and research scientists providing the highest levels of support to users. Application scientists from Biacore are available to work directly with customers in their laboratories to help and guide in the development and design of assay methodology, again with the aim of accelerating the secondary screening applications process.

"Biacore S51 represents a major advance in analytical instrumentation for drug discovery and development in terms of both the quality and quantity of information obtained from a single assay," said Julian Abery, VP and Head of the Pharmaceutical and Biotechnology Business Unit at Biacore. "Biacore is dedicated to providing new and enabling technologies to the drug discovery and development market, and we believe Biacore S51 will be well received. We continue to develop advanced instrumentation to remove bottlenecks at critical stages of lead candidate compound verification. At the same time, we believe our new TecEdge program will facilitate a unique relationship between Biacore and drug development research scientists focused on providing detailed information and identifying new opportunities."
COPYRIGHT 2001 Millin Publishing, Inc.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2001, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:Biacore S51
Comment:BIACORE'S NEW ADVANCED SYSTEM SET TO DRAMATICALLY REDUCE DRUG DISCOVERY AND DEVELOPMENT BOTTLENECKS; BIACORE LAUNCHES NEW HIGH PERFORMANCE ANALYTICAL SYSTEM.(Biacore S51)
Publication:EDP Weekly's IT Monitor
Article Type:Product Announcement
Geographic Code:4EUSW
Date:Aug 27, 2001
Words:444
Previous Article:IBM AND EDOCS ANNOUNCE GLOBAL STRATEGIC ALLIANCE TO PROVIDE ONLINE ACCOUNT MANAGEMENT AND E-BILLING FOR GLOBAL 2000 COMPANIES.
Next Article:INTERFACE SOFTWARE ANNOUNCES AVAILABILITY OF INTERACTION GADGET WEB SERVICES FOR THE PLUMTREE CORPORATE PORTAL.
Topics:


Related Articles
Perkin-Elmer's Tropix Subsidiary to Accelerate Drug Discovery Through Pharmaceutical Screening Service.
Oceanix Biosciences Corp. and Glaxo Wellcome Inc. Enter Into Collaborative Research and Database Access Agreement for the NovaScreen Receptor...
Biacore Enters Collaboration with SmithKline Beecham; Further Deal Validates the Value of Biacore's Technology to the Drug Discovery Industry.
SmithKline Beecham Using LJL BioSystems' First FLARe System to Screen Difficult Compounds; Successful Completion of Another Major Collaboration...
Biacore and Pharmacia Corporation Collaborate; Deal Validates the Value of Biacore's Technology in Drug and Serum Protein Binding Studies.
Biacore and Boehringer Ingelheim Develop SPR System for Improved Drug Manufacturing Quality Control.
Eli Lilly and Company, Indiana University and Purdue University Join Forces; Unique Partnership Seeks to Advance the Study of Proteomics.
NEC to Unveil New Molecular Dynamics Computational Server.
Model-Oriented Knowledgebases (KBs) Can Accelerate the Drug Discovery Process by Reducing the Time Spent on These Processes.
GNI SYSTEMS PHARMACOLOGY RESEARCH INSTITUTE LAUNCHED.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters